ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cyramza (ramucirumab) — U.S. revenue [legacy] by Year
Cyramza (ramucirumab) — U.S. revenue ($M) [legacy] ($M)
Eli Lilly Cyramza (ramucirumab) — U.S. revenue [legacy]: $442M in FY2024, up 9.9% from a year earlier. That is the highest of the 9 years on record here. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-19) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cyramza (ramucirumab) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 442 | +9.9% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 402 | +14.5% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 351 | -1.9% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 358 | -6.2% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 382 | +13.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 335 | +15.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 292 | +4.6% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 279 | +3.2% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 270 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cyramza (ramucirumab) — U.S. revenue [legacy] ($M), annual FY2016–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-cyramza-us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.